4 years of historical data (2021–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CG Oncology, Inc. Common stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $4.6B | $1.8B | — | — | — |
| Enterprise Value | $4.3B | $1.5B | — | — | — |
| P/E Ratio → | -41.70 | — | — | — | — |
| P/S Ratio | 4041.01 | 1573.67 | — | — | — |
| P/B Ratio | 5.01 | 2.44 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 1348.18 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
CG Oncology, Inc. Common stock earns an operating margin of -10067.3%. Operating margins have expanded from -18453.4% to -10067.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -19.2% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 92.1% | 99.9% |
| Operating Margin | -10067.3% | -10067.3% | -27180.9% | -18453.4% | -121.7% |
| Net Profit Margin | -7729.5% | -7729.5% | -23827.0% | -18556.5% | -124.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -19.2% | -19.2% | -31.4% | -42.8% | -31.9% |
| ROA | -18.5% | -18.5% | -28.0% | -34.3% | -21.9% |
| ROIC | -26.3% | -26.3% | -36.1% | -96.6% | — |
| ROCE | -25.0% | -25.0% | -34.9% | -38.1% | -23.9% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $257M exceeds total debt of $238000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.13 | 0.38 |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.04 | -0.58 | -0.96 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | -35246.00 | -27.95 |
Net cash position: cash ($257M) exceeds total debt ($238000)
Short-term solvency ratios and asset-utilisation metrics
CG Oncology, Inc. Common stock's current ratio of 35.30x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.54x to 35.30x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 35.30 | 35.30 | 13.62 | 9.54 | 9.78 |
| Quick Ratio | 35.30 | 35.30 | 13.62 | 9.54 | 9.78 |
| Cash Ratio | 34.72 | 34.72 | 13.17 | 9.30 | 8.97 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.18 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | 250.28 | 164.61 | 579.03 | 0.07 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CG Oncology, Inc. Common stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $62M | $67M | $67M | $67M |
Compare CGON with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CGONYou | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| IBRX | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| RCUS | $3B | -6.2 | — | — | — | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 4 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CGON stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonCG Oncology, Inc. Common stock's current P/E ratio is -41.7x. This places it at the 50th percentile of its historical range.
CG Oncology, Inc. Common stock's return on equity (ROE) is -19.2%. The historical average is -31.3%.
Based on historical data, CG Oncology, Inc. Common stock is trading at a P/E of -41.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CG Oncology, Inc. Common stock has 100.0% gross margin and -10067.3% operating margin.